Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1188265-73-7

Post Buying Request

1188265-73-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1188265-73-7 Usage

Description

Benzyl 3-aminocyclobutylcarbamate is a chemical compound with the formula C14H20N2O2, belonging to the carbamate class of compounds. It features a carbonyl group attached to an oxygen and a nitrogen atom, with a hydrocarbon benzyl group derived from benzene and a four-membered cyclic 3-aminocyclobutyl group containing an amino group. This unique structure and its properties render benzyl 3-aminocyclobutylcarbamate a valuable building block in the pharmaceutical industry for the synthesis of various drugs and biologically active molecules.

Uses

Used in Pharmaceutical Industry:
Benzyl 3-aminocyclobutylcarbamate is used as a precursor for the synthesis of various drugs and biologically active molecules due to its unique structure and properties, which make it a valuable building block in the development of new pharmaceutical compounds. Its potential applications include the creation of novel therapeutic agents and the enhancement of existing drug formulations.

Check Digit Verification of cas no

The CAS Registry Mumber 1188265-73-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,8,8,2,6 and 5 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1188265-73:
(9*1)+(8*1)+(7*8)+(6*8)+(5*2)+(4*6)+(3*5)+(2*7)+(1*3)=187
187 % 10 = 7
So 1188265-73-7 is a valid CAS Registry Number.

1188265-73-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name tert-butyl 3-(2-hydroxyethyl)piperazine-1-carboxylate

1.2 Other means of identification

Product number -
Other names AS-P1

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1188265-73-7 SDS

1188265-73-7Downstream Products

1188265-73-7Relevant articles and documents

Structure-based design and pharmacokinetic optimization of covalent allosteric inhibitors of the mutant gtpase krasg12c

Kettle, Jason G.,Bagal, Sharan K.,Bickerton, Sue,Bodnarchuk, Michael S.,Breed, Jason,Carbajo, Rodrigo J.,Cassar, Doyle J.,Chakraborty, Atanu,Cosulich, Sabina,Cumming, Iain,Davies, Michael,Eatherton, Andrew,Evans, Laura,Feron, Lyman,Fillery, Shaun,Gleave, Emma S.,Goldberg, Frederick W.,Harlfinger, Stephanie,Hanson, Lyndsey,Howard, Martin,Howells, Rachel,Jackson, Anne,Kemmitt, Paul,Kingston, Jennifer K.,Lamont, Scott,Lewis, Hilary J.,Li, Songlei,Liu, Libin,Ogg, Derek,Phillips, Christopher,Polanski, Radek,Robb, Graeme,Robinson, David,Ross, Sarah,Smith, James M.,Tonge, Michael,Whiteley, Rebecca,Yang, Junsheng,Zhang, Longfei,Zhao, Xiliang

supporting information, p. 4468 - 4483 (2020/06/08)

Attempts to directly drug the important oncogene KRAS have met with limited success despite numerous efforts across industry and academia. The KRASG12C mutant represents an "Achilles heel" and has recently yielded to covalent targeting with small molecules that bind the mutant cysteine and create an allosteric pocket on GDP-bound RAS, locking it in an inactive state. A weak inhibitor at this site was optimized through conformational locking of a piperazine-quinazoline motif and linker modification. Subsequent introduction of a key methyl group to the piperazine resulted in enhancements in potency, permeability, clearance, and reactivity, leading to identification of a potent KRASG12C inhibitor with high selectivity and excellent cross-species pharmacokinetic parameters and in vivo efficacy.

Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection

-

Paragraph 0441; 0442; 0443, (2015/11/02)

The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R6, X, Y, W and n are as described herein, compositions including the compounds and methods of using the compounds.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

-

Page/Page column 49, (2013/03/26)

The present invention provides compounds of Formula Ia and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1188265-73-7